Recent advances in the medical management of Takayasu arteritis: An update on use of biologic therapies

Current Opinion in Rheumatology

Volumn 26, Issue 1, 2014, Pages 7-15

  Clifford, Alison ^a   Hoffman, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

adalimumab; anti TNF; etanercept; infliximab; large vessel vasculitis; rituximab; Takayasu arteritis; tocilizumab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ENDOTHELIAL CELL ANTIBODY; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY PRODUCTION; AORTA ARCH SYNDROME; APPLICATION SITE REACTION; ARTERY LESION; BIOLOGICAL THERAPY; CD4+ T LYMPHOCYTE; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FOLLOW UP; GAMMA DELTA T LYMPHOCYTE; GRANULOMA; HUMAN; INFECTION; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; STEROID THERAPY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; TAKAYASU ARTERITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890178714     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000004     Document Type: Review

References (49)

1. HoffmanGS. Treatment of resistant Takayasu's arteritis. Rheum Dis Clin N Am 1995; 21:73-80.
2. Kotter I, Henes JC, Wagner AD, et al. Does glucocorticosteroid-resistant large vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30 (1 Suppl 70):S114-S129.
3. Hoffman GS, Leavitt RY, Kerr GS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-582.
4. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68:318-323.
5. Goel R, Danda D, Matthew J, Edwin N. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol 2010; 29:329-332.
6. Wen D, Du X, Ma CS. Takayasu arteritis: Diagnosis, treatment and prognosis. Int Rev Immunol 2012; 31:462-473.
7. Arnaud L, Haroche J, Mathian A, et al. Pathogenesis of Takayasu's arteritis: A 2011 update. Autoimmun Rev 2011; 11:61-67.
8. Vaideeswar P, Deshpande Jr. Pathology of Takayasu arteritis: A brief review. Ann Pediatr Cardiol 2013; 6:52-58.
9. Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis. Clin Exp Immunol 2004; 138:369-374.
10. Tripathy NK, Gupta PC, Nityanand S. High TNF alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol 2006; 118:154-158.
11. Hoffman GS, Merkel PA, Brasington RD, et al. Antitumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50:2296-2304.
12. Molloy ES, Langford CA, Clark TM, et al. Antitumor necrosis factor therapy in patients with refractory Takayasu arteritis: Long-term follow-up. Ann Rheum Dis 2008; 67:1567-1569.
13. Karageorgaki ZT, Mavragani CP, Papathanasiou MA, Skopouli FN. Infliximab in Takayasu arteritis: A safe alternative? Clin Rheumatol 2007; 26:984-987.
14. Tanaka F, Kawakami A, Iwanaga N, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 2006; 45:313-316.
15. Calderon R, Estrada S, Ramirez de la Piscina P, et al. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis. Rev Esp Enferm Dig 2010; 102:145-146.
16. Buonuomo PS, Bracaglia C, Campana A, et al. Infliximab therapy in pediatric Takayasu's arteritis: Report of 2 cases. Rheumatol Int 2011; 31:93-95.
17. Jolly M, Curran JJ. Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis. J Clin Rheumatol 2005; 11:213-215.
18. Maffei S, Di Renzo M, Santoro S, et al. Eur Rev Med Pharmacol Sci 2009; 13:63-65.
19. Tato F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal antitumor necrosis factor antibody adalimumab. Int Angiol 2005; 24:304-307.
20. Gesce K, Ruzsa Z, Nagy F, et al. Successful infliximab treatment in a patient with Takayasu arteritis associated with ulcerative colitis or migration does not override genetics. Inflamm Bowel Dis 2011; 17:E69-E70.
21. Nunes G, Neves FS, Melo FM, et al. Takayasu arteritis: Anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol 2010; 50:291-298.
22. Katoh N, Kubota M, Shimojima Y, et al. Takayasu's arteritis in a patient with Crohn's disease: An unexpected association during infliximab therapy. Intern Med 2010; 49:179-182.
23. Osman M, Aaron S, Noga M, Yacyshyn E. Takayasu's arteritis progression on anti-TNF biologics: A case series. Clin Rheumatol 2011; 30:703-706.
24. Filocamo G, Buoncompagni A, Viola S, et al. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J Pediatr 2008; 153:432-434.
25. Della Rossa A, Tavoni A, Merlini G. Two Takayasu arteritis patients successfully treated with infliximab: A potential disease-modifying agent? Rheumatology (Oxford) 2005; 44:1074-1075.
26. Mekinian A, Neel A, Sibilia J, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 2012; 51:882-886.
27. Comormand C, Plaisier E, Dahan K, et al. Anti TNF-alpha in refractory Takayasu's arteritis: Cases series and review of the literature. Autoimmun Rev 2012; 11:678-684.
28. Quartuccio L, Schiavon F, Zuliani F, et al. Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's artertitis treated with infliximab. Clin Exp Rheuamatol 2012; 30:922-928.
29. Schmidt J, Kermani TA, Bacani AK, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with longterm follow-up. Arthritis Care Res (Hoboken) 2012; 64:1079-1083.
30. Killinger Z, Cierny D, Jackuliak P, et al. Long-term efficacy of infliximab for treating Takayasu arteritis. Isr Med Assoc J 2012; 14:771-773.
31. Alten R, Maleitzke T. Tocilizumab: A novel humanized antiinterleukin 6 (IL-6 receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med 2013; 45:357-363.
32. Seko Y, Sato O, Takagi A, et al. Restricted usage of T-cell receptor Valpha- Vbeta genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation 1996; 93:1788-1790.
33. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006; 45:545-548.
34. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin 6 receptor antibody. Arthritis Rheum 2008; 58:1197-1200.
35. Unizony S, Stone JH, Stone Jr. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013; 25:3-9.
36. Bravo Mancheno B, Perin F, Guez Vazquez Del Rey Mdel M, et al. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics 2012; 130:e1720-e1724.
37. Xenitidis T, Horger M, Zeh G, et al. Sustained inflammation of the aortic wall despite tocilizumab treatment in two cases of Takayasu arteritis. Rheumatology (Oxford) 2013; 52:1729-1731.
38. Abisror N, Mekinian A, Lavigne C, et al. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. Autoimmun Rev 2013; 12:1143-1149.
39. Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011; 141:w13156.
40. Bredemeier M, Rocha CM, Barbosa MV, Pitrez EH. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012; 30 (1 Suppl 70):S98- 100.
41. Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51:151- 156.
42. Salvarani C, Magnani L, Catanoso MG, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012; 30 (1 Suppl 70):S90-S93.
43. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012; 64:1720-1729.
44. Tso E, Flamm SD, White RD, et al. Takayasu arteritis: Utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46:1634-1642.
45. Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: Involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg 2000; 8:141-148.
46. Park MC, Park YB, Jung SY, et al. Antiendothelial cell antibodies and antiphospholipid antibodies in Takayasu's arteritis. Correlations of their titers and isotype distributions with disease activity. Clin Exp Rheum 2006; 24 (2 Suppl 41):S10-S16.
47. Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012; 71:75-79.
48. Galarza C, Valencia D, Tobon GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008; 34:124-128.
49. Ernst D, Greer M, Stoll M, et al. Remission achieved in refractory advanced takayasu arteritis using rituximab. Case Rep Rheumatol 2012; 2012:406963.